Key Takeaways
- InvestHK will showcase Hong Kong as a global launchpad for biotechnology at the BIO International Convention 2026.
- A delegation from Hong Kong includes over 20 life science companies and several universities, emphasizing the city’s role in international market access.
- Government support and regional connectivity make Hong Kong an attractive base for biotechnology expansion.
Hong Kong Showcases Biotechnology Potential at BIO International Convention 2026
Invest Hong Kong (InvestHK) is set to promote Hong Kong as a key launchpad for life sciences and health technology companies at the BIO International Convention 2026, taking place from June 22-25 at the San Diego Convention Center. This event is among the largest in the global biotechnology sector.
Leading the delegation, Mr. Andy Wong, Head of Innovation & Technology and Life & Health Sciences at InvestHK, will accompany over 20 Hong Kong-based life science firms, five universities, and 15 university spin-offs. The event will feature a Hong Kong pavilion where company showcases, pitching sessions, and networking events will connect attendees with global investors and industry leaders. This initiative aims to highlight how Hong Kong serves as an entry point to Asia and a springboard for companies seeking to expand internationally.
Key participants include notable enterprises such as SPH Biotherapeutics (HK) Limited, Canton Biologics, and Great Bay Bio Limited, all of which view Hong Kong as a platform for connecting with international capital and partners, effectively transforming local innovations into global opportunities.
InvestHK is actively supporting these companies’ global strategies, aiding in market entry, business setups, and establishing connections with investors and research partners worldwide. Mr. Wong emphasized the importance of strengthening ties with the U.S. biotech sector during this event, noting that Hong Kong offers a strong foothold in Asia and a clear pathway for global growth facilitated by top-tier research talent and infrastructure, along with robust intellectual property protection.
He also pointed out the various government incentives, such as the ‘1+’ mechanism for expedited drug approval and funding schemes designed to bolster research and innovation. The recent development of an extensive innovation hub in the Northern Metropolis further enhances Hong Kong’s attractiveness for life sciences firms.
The BIO International Convention is expected to gather over 20,000 industry leaders from more than 76 countries, making it a prime platform for Hong Kong to assert its position in the global biotechnology ecosystem. By participating, Hong Kong seeks to foster international collaboration and promote its unique offerings in the life sciences sector.
The content above is a summary. For more details, see the source article.
